This special issue commemorates the 10th anniversary of Institute of Biomedical Sciences (IBMS), East China Normal University (ECNU). IBMS was established in 2007 by a group of oversea scientists from Harvard Medical School, Yale University, the Texas A&M University, Baylor College of Medicine, the University of Texas MD Anderson Cancer Center, the University of California and the Scripps Research Institute. These scientists were brought together on the initiative of Dr. Mingyao Liu, who was then appointed as the director of IBMS and dean of School of Life Sciences, ECNU. The institute is located on the new ECNU campus in Minhang district of Shanghai. IBMS has a mission to promote and advance biological and medical sciences in all their forms through research, education, communication and collaboration. The main purpose of IBMS is to conduct forefront basic and applied research in cell signaling transduction and regulatory biology. Its research focus includes gene transcriptional regulation, protein modification, stem cell and developmental regulation, and innovative drug discovery. In 2011, the institute was awarded with the title of Shanghai Key Laboratory of Regulatory Biology, with the direct support from Shanghai Municipal Science and Technology Commission. In 2013, it won the most outstanding laboratory in Shanghai.
As one of the centers for education and research in China, IBMS tries to lead the way in research and application of medical sciences. From the first founding with a few scientists to a big team composed of outstanding young and senior scientists in multifaceted research areas today, the growth of the IBMS is quite promising. IBMS currently has 16 independent research groups and more than 60 full-time faculties and staffs. IBMS has totally received more than 150 grants from the Ministry of Science and Technology, the Ministry of Education, and the National Natural Science Foundation of China, as well as Shanghai Municipal Science and Technology Commissions.. During the past 10 years, members of IBMS have published more than 300 articles in peer-reviewed and high-impact journals, including Nature Biotechnology, Nature Medicine, Immunity, Nature Protocols, Cell Metabolism, Nature Communications, Molecular Cell, Proceedings (Chen et al., 2017) . Dr. Yuping Lai is interested in the exploration of underlying mechanisms in wound healing and psoriasis. In this issue, her study shows that activation of Toll-like receptor 3 signaling induces keratinocyte differentiation by upregulation of S100A7 (psoriasin) (Lei et al., 2017) . Dr. Yuan Wang's research has been focused on the genetic programs that govern hematopoietic development and germ cell differentiation from embryonic stem cells. By utilizing an in vitro differentiation system of mouse embryonic stem cells, Dr. Yuan Wang and her co-workers identify several microRNAs with unknown functions that are highly enriched in embryonic hematopoietic cells (Gong et al, 2017) . Dr. Tieliu Shi's research focuses are on data analyses with integration of multi-level data (including NGS sequencing data, Proteomics data and clinical data, etc.) for disease genes, disease mechanisms and biomarker discoveries and prediction of gene regulatory network and protein-protein interaction. His group systematically compares human orthologs with mouse orthologs in terms of alternative splicing patterns and expression profiles (Chen et al, 2017) , and annotates genomes using RNA-seq data (Chen et al., 2017) . Dr. Min Qian and her team's research focuses on the molecular mechanisms of macrophage mediated innate immune responses in inflammation, cancer and infectious diseases. They reveal that Presenilin 2 (PS2) deficiency facilitates Aβ-induced neuroinflammation and injury by upregulating P2X7 expression, which provide a potential new mechanism for Alzheimer's disease (Qin et al, 2017) . The rest three articles of this special issue are contributed by the team led by Dr. Mingyao Liu. His team has been focused on basic research to understand physiological functions of G-protein coupled receptors, and translational research to discover innovative drugs by targeting critical cell signaling pathways in cancers. Dr. Mingyao Liu and his colleagues summarize molecular targets of human gastric cancer based on collaborative sequencing data (Guo et al, 2017) , discover a novel angiogenesis inhibitor (Liu et al., 2017) and set up pharmacokinetic platform to evaluate compounds' activity on metabolic enzymes (Lu et al, 2017) . Besides the above research groups, there are other groups in IBMS that focus on structure biology, immunology, synthetic biology and functional proteomics.
IBMS has been working on building leadership in biomedical research and sciences during the past 10 years. We hope that IBMS will create more significant knowledge and apply more science and discoveries to further education, and this goal will be realized through collaborative research across disciplines and specialties locally and globally. Wong's laboratory has long been interested in epigenetic regulation and transcriptional regulation by nuclear hormone receptors (NRs). His group has made contribution to the identification and characterization of the corepressor complexes of nuclear hormone receptors, histone demethylases and identification and characterization of histone code effectors. He has published more than 100 peer-reviewed papers. His current research focuses on epigenetic regulation including DNA methylation and histone modifications. Wang's lab is to dissect the genetic programs that govern germ cell and blood differentiation using both in vitro differentiation system of PSCs and gene modified mouse models. She is also interested in molecular mechanism that regulates self-renewal of PSCs.
Dr. Min Qian completed her B.S. degree at East China Normal University in 1983. After that, she earned her Master degree at East China Normal University in 1986. Then, she began her assistant professor position at Suzhou University of Science and Technology from 1986 to 1988. She obtained her PhD degree at East China Normal University in 1991 and then served as an assistant professor at East China Normal University, and has been a full professor of immunology since 2002. She is interested in exploring specific human antibody to different drug targets by using phage display technology. Meanwhile, she is also involved in understanding the regulation of innate immune responses in inflammation, cancer and infectious diseases.
Dr. Bing Du completed his B.S. degree in biochemistry from Anhui University in 2001. After that, he earned his Ph.D. degree in biochemistry and molecular biology at East China Normal University in 2006. Since then, he began his assistant professor position at East China Normal University, and is now an associate professor of immunology from 2010. In this period, he joined Dr. Mingyao Liu's laboratory as a visiting scholar for more than 1 year at Texas A&M Institute of Biosciences and Technology in Houston. His research interests are in understanding the molecular mechanisms of macrophage mediated innate immune responses in inflammation, cancer and infectious diseases.
